One clue was MNTA's announcements regarding the FDA inspections of their (Sandoz's) manufacturing facilities & suppliers. Teva could be getting those inspections, but since their enoxaparin program is probably not considered material from a strictly legal perspective, they are not obligated to publicize them, and may not feel like it. A good fishing question for an analyst to ask Teva at the next opportunity: "Has the FDA inspected your enoxaparin manufacturing facilities?"
Regards, RockRat
Market Data 
Markets 
AI
